 Skye Bioscience inc OTCQB:SKYE announced that it has entered into an agreement with Novotech Health Holdings, a leading full-service contract research organization CRO in Asia-Pacific, for the upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma. We are pleased to bring on one of Asia-Pacifics premier biotech specialist CROs to support our first-inhuman clinical study, said Punit Dhillon, CEO of Skye Bioscience, in a statement. 